Open Medicine EU

Archives for Uncategorized

Could it happen here?

There have been many serious cases of mis-selling and off-label promotion of medicines in the US. Could the same thing be happening here, or do pharmaceutical companies behave better on this side of the Atlantic? For my BMJ blog I compiled a table of cases taken by the US Department of Justice since 2004 involving… » read more

Posted by Jim Murray

Blogging at the BMJ

The British Medical Journal have invited me to be a guest blogger. My first effort has just been published, and you can see it here But, don’t worry! I will continue with this blog.

Posted by Jim Murray

I made a personal submission to the EMA Consultation on the Publication and Access to Clinical-Trial Data, which you will find here. As I said in the submission, public consultations are more effective when it is possible … to comment on submissions from others. My submission was partly in the form of a comment on… » read more

Posted by Jim Murray

The Report on Clinical Trials agreed yesterday in the ENVI Committee would bring more transparency than before, but less than was originally proposed by the Rapporteur, Glenis Wilmott. She had proposed the publication of a Clinical Study Report within one year of the completion or termination of a trial. The compromise agreed a two stage… » read more

Posted by Jim Murray

The proposal for the revision of the Clinical Trials Directive will be discussed tomorrow (29th May) in the Envi Committee of the European Parliament. On transparency and disclosure of trial results I am not hearing good news. The rapporteur, Glenis Wilmott, made a good proposal in her report – for the publication of a Clinical… » read more

Posted by Jim Murray

Like AbbVie, described in my last post, a second American company, InterMune, has taken legal action to prevent or restrict the European Medicines Agency from disclosing certain clinical trial data after a medicine is approved for marketing. On 4th March a federal appeals court upheld the conviction of the former chief executive of InterMune, W.… » read more

Posted by Jim Murray

Two American pharmaceutical companies, AbbVie and Intermune, have taken legal action to prevent or restrict the European Medicines Agency from disclosing certain clinical trial data after a medicine is approved for marketing. In my opinion, both companies have been involved in activities that seem to prove the need for more transparency and not less. AbbVie… » read more

Posted by Jim Murray

EurActiv a publié aujourd’hui une version française de mon article au sujet de la proposition de règlement de la Commission révisant la directive relative aux essais cliniques qui sera discuté cette semaine au sein de la Commission Environnement, santé publique et sécurité alimentaire. Vous trouverez l’article ici.

Posted by Jim Murray